Drug intelligence / Profile preview

cyclophosphamide + docetaxel + epirubicin + fluorouracil + goserelin + tamoxifen

Development stage: Preclinical
Lead developer: Takeda
Modality: Small Molecules
Administration: Intravenous, Oral, Subcutaneous

Overview

This is a combination therapy consisting of six different drugs used in breast cancer treatment. The combination includes: - Cyclophosphamide: An alkylating agent that works by damaging DNA and preventing cancer cell division - Docetaxel (Taxotere): A taxane that disrupts microtubule function essential for cell division - Epirubicin: An anthracycline antibiotic that interferes with DNA and RNA synthesis - Fluorouracil: An antimetabolite that interferes with DNA synthesis - Goserelin: A luteinizing hormone-releasing hormone (LHRH) agonist that suppresses ovarian function in premenopausal women - Tamoxifen: A selective estrogen receptor modulator (SERM) that blocks estrogen receptors This combination likely represents a comprehensive approach to treating hormone receptor-positive breast cancer in premenopausal women, combining chemotherapy agents with hormonal therapy.

Targets

ER (Estrogen receptor)TUBB (Tubulin (alpha and beta subunits))TS (Thymidylate synthase)TOP2A (DNA topoisomerase II)DNAGnRHR (Gonadotropin-releasing hormone receptor)

Beyond the preview

Go deeper on cyclophosphamide + docetaxel + epirubicin + fluorouracil + goserelin + tamoxifen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cyclophosphamide + docetaxel + epirubicin + fluorouracil + goserelin + tamoxifen.

Explore the full profile